STOCK TITAN

Aclarion Inc - ACON STOCK NEWS

Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.

Aclarion, Inc. (NASDAQ: ACON) is a leading healthcare technology company specializing in the innovative use of Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. Their flagship product, Nociscan, is a unique Software as a Service (SaaS) platform that noninvasively assists physicians in distinguishing between painful and nonpainful discs in the spine. By leveraging advanced MRS technology, Nociscan helps to identify the specific source of chronic low back pain (cLBP), a condition affecting 266 million people globally.

Nociscan generates reports based on MRS data collected from MRI machines, quantifying chemical biomarkers associated with disc pain. This data enables physicians to tailor treatment strategies optimally. The company derives its revenue primarily from the delivery of these Nociscan reports to medical professionals across the United States, enhancing their ability to make informed clinical decisions.

Recent developments highlight the company’s accelerated growth and significant milestones. Aclarion recently completed its 1,000th commercial Nociscan exam, marking an exciting phase of adoption. Moreover, the company is expanding Nociscan's compatibility beyond Siemens MRI machines, increasing its accessibility worldwide. The strategic partnership with Alphatec Spine, Inc. aims to integrate Nociscan into ATEC's AlphaInformatiX platform, providing comprehensive data to improve surgical decision-making for spine surgery.

The company is also initiating the pivotal multicenter, prospective, randomized CLARITY trial to validate superior surgical outcomes when Nociscan is integrated into surgical decision processes. Furthermore, Aclarion’s involvement in the LIFEHAB Trial in Norway underscores its commitment to advancing scientific understanding of chronic low back pain and improving patient outcomes.

Aclarion’s innovative approach is well-supported by a robust patent portfolio, including 22 U.S. patents and numerous international patents. The company's mission is to set a new standard of care in spinal diagnostics by offering noninvasive, data-driven insights that enhance the effectiveness of low back pain treatments.

Rhea-AI Summary

Aclarion (Nasdaq: ACON) announced the first payer coverage of its Nociscan technology by AXA in Greater London, UK, in cooperation with The London Clinic. AXA, the second largest provider of private medical insurance in the UK, covers about 30% of the private medical insurance market with around 3 million insured clients. This endorsement marks a significant milestone for Aclarion, paving the way for widescale commercialization and broader adoption of Nociscan, a tool designed to assist physicians in diagnosing chronic low back pain. The decision is expected to improve patient outcomes significantly and drive future revenue growth for Aclarion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.21%
Tags
none
-
Rhea-AI Summary

Aclarion has extended its commercial agreement with The London Clinic to increase the use of Nociscan, a technology that helps identify the location of chronic low back pain. The new contract sets a higher price for Nociscan and includes efforts to secure payer coverage from private health insurers. The London Clinic, a renowned private hospital, will also work to expand access to Nociscan for patients and referring physicians throughout Greater London. The extension follows compelling results from an initial evaluation involving 20 patients. CEO Brent Ness highlighted the importance of the UK market and expressed confidence in achieving similar results in the U.S. market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
-
Rhea-AI Summary
Aclarion's Nociscan Solution will be utilized in the LIFEHAB Trial in Norway, a randomized controlled trial comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation for chronic low back pain. The trial aims to enroll 202 patients with back pain greater than 1 year in duration. Nociscan is the first evidence-supported SaaS platform to help physicians distinguish between painful and nonpainful discs in the lumbar spine using chemical biomarkers and proprietary algorithms. Aclarion sees this trial as a significant step towards successful reimbursement in Norway's national health insurance system, targeting enrollment to start in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.46%
Tags
none
Rhea-AI Summary
Aclarion, Inc. confirms the predictive value of Nociscan for identifying painful discs. Nociscan demonstrated 100% sensitivity and 80% specificity compared to provocative discography, providing surgeons with better information. The clinical paper published in the International Journal of Spine Surgery establishes Nociscan as a noninvasive method to identify painful lumbar discs, potentially improving surgical outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.13%
Tags
none
-
Rhea-AI Summary
Aclarion, Inc. closes public offering of 5,175,000 units, raising approximately $3.0 million. Each unit sold at $0.58 includes one share of common stock (or pre-funded warrant), and two common warrants. The common warrants are exercisable at $0.58 per share and expire in five years. Maxim Group LLC acted as the sole placement agent. The offering was made under a registration statement declared effective by the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
-
Rhea-AI Summary
Aclarion, Inc. announced the pricing of a public offering of 5,175,000 units at $0.58 per unit, expecting gross proceeds of approximately $3.0 million. The offering includes common stock, pre-funded warrants, and common warrants, with Maxim Group LLC acting as the sole placement agent. The offering is expected to close on February 27, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-60.55%
Tags
Rhea-AI Summary
Aclarion, Inc. (ACON) has initiated the CLARITY trial to validate superior surgical outcomes using Nociscan technology. The recent financing transactions have significantly reduced debt and increased available cash, enabling the company to achieve key milestones. The strategic partnership with Alphatec is expected to onboard 5 additional Key Opinion Leader surgeons and increase Nociscan orders. The CLARITY trial will enroll up to 300 patients across 8 sites, with principal investigator Nicholas Theodore, MD, leading the study. Aclarion also aims to add 5 new KOL surgeons to the Nociscan network in the first half of 2024 through the strategic partnership with Alphatec.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
partnership
-
Rhea-AI Summary
Aclarion, Inc. announces the availability of Nociscan, their diagnostic solution for chronic low back pain, at the Barrow Neurological Institute in Phoenix, AZ. Dr. Juan Uribe, a renowned neurosurgeon, is now the 3rd key opinion leader with access to the diagnostic center. Nociscan aims to help physicians identify the location of chronic low back pain noninvasively through chemical biomarkers and proprietary algorithms. The activation of the Phoenix market is expected to support scan volume growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.12%
Tags
none
-
Rhea-AI Summary
Aclarion, Inc. (Nasdaq: ACON, ACONW) announced the product release of Nociscan 2.6, expanding accessibility on the worldwide MRI market. This new release includes support for additional leading MRI scanners beyond those manufactured by Siemens, a major milestone towards making Nociscan available on the leading MRI machines of all manufacturers. The company aims to improve the lives of millions of patients suffering from degenerative spine disease and low back pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.7%
Tags
none
Rhea-AI Summary
Aclarion, Inc. (Nasdaq: ACON, ACONW) partners with Alphatec Spine, Inc. (Nasdaq: ATEC) to integrate Aclarion’s Nociscan technology, the first augmented intelligence platform to measure pain biomarkers in the lumbar spine, into ATEC’s AlphaInformatiX platform. The partnership aims to improve clinical outcomes and reduce procedural costs for patients with chronic low back pain, leveraging ATEC’s surgeon network and providing ATEC with exclusive distribution rights for Nociscan. Aclarion’s published trials confirm the comparative advantage of Nociscan in achieving differentiated surgical outcomes, with a peer-reviewed publication demonstrating an 85% success rate at two years for discogenic low back pain surgeries consistent with Nociscan-identified discs, compared to 63% for inconsistent treatment strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.65%
Tags
partnership

FAQ

What is the current stock price of Aclarion (ACON)?

The current stock price of Aclarion (ACON) is $7.6 as of March 3, 2025.

What is the market cap of Aclarion (ACON)?

The market cap of Aclarion (ACON) is approximately 5.7M.

What does Aclarion, Inc. do?

Aclarion, Inc. is a healthcare technology company specializing in Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments, particularly for chronic low back pain.

What is Nociscan?

Nociscan is Aclarion’s SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the spine by analyzing MRS data and quantifying biomarkers associated with disc pain.

How does Aclarion generate revenue?

Aclarion generates revenue from the delivery of Nociscan reports to medical professionals, primarily in the United States.

What recent achievements has Aclarion made?

Aclarion recently completed its 1,000th commercial Nociscan exam, accelerated compatibility with various MRI machines, and initiated the pivotal CLARITY trial. They also formed a strategic partnership with Alphatec Spine, Inc.

What is the CLARITY trial?

The CLARITY trial is a multicenter, prospective, randomized clinical trial designed to validate the superior surgical outcomes when Nociscan is used in surgical decision-making for patients with chronic low back pain.

What partnerships has Aclarion formed?

Aclarion has formed a strategic partnership with Alphatec Spine, Inc. to integrate Nociscan into ATEC's AlphaInformatiX platform, enhancing surgical decision-making with comprehensive data.

What is the significance of Nociscan's compatibility with different MRI machines?

Expanding Nociscan’s compatibility to include MRI machines beyond Siemens increases its accessibility to healthcare providers and patients worldwide, facilitating broader adoption of the technology.

What is the LIFEHAB trial?

The LIFEHAB trial is a randomized controlled study in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation. Nociscan will be used to provide insights into the diagnosis and treatment of chronic low back pain.

How does Nociscan improve surgical outcomes?

Studies indicate that Nociscan improves surgical outcomes by providing precise, noninvasive identification of painful discs, helping physicians to optimize treatment strategies and achieve better patient results.

What is Aclarion's patent portfolio like?

Aclarion holds 22 U.S. patents, numerous international patents, and several pending applications, demonstrating a strong intellectual property position supporting their innovative technologies.
Aclarion Inc

Nasdaq:ACON

ACON Rankings

ACON Stock Data

5.74M
1.02M
9.77%
3.58%
4.27%
Health Information Services
Services-medical Laboratories
Link
United States
BROOMFIELD